Multicenter phase i trial of the mitogen-activated protein kinase 1/2 inhibitor bay 86-9766 in patients with advanced cancer

Clinical Cancer Research

Volumn 19, Issue 5, 2013, Pages 1232-1243

  Weekes, Colin D ^a   Von Hoff, Daniel D ^b,c   Adjei, Alex A ^d   Leffingwell, Diane P ^e   Eckhardt, S Gail ^a   Gore, Lia ^a   Lewis, Karl D ^a   Weiss, Glen J ^b,c   Ramanathan, Ramesh K ^b,c   Dy, Grace K ^d   Ma, Wen W ^d   Sheedy, Beth ^e   Iverson, Cory ^e   Miner, Jeffrey N ^e   Shen, Zancong ^e   Yeh, Li Tain ^e   Dubowy, Ronald L ^f   Jeffers, Michael ^f   Rajagopalan, Prabhu ^f   Clendeninn, Neil J ^e  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Virginia G Piper Cancer Center   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e Ardea Biosciences Inc   (United States)

^f BAYER CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BAY 86 9766; BEVACIZUMAB; EMOLLIENT AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABNORMAL DREAMING; ACNE; ADRENAL CANCER; ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHORIORETINOPATHY; COHORT ANALYSIS; COLORECTAL CANCER; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ENZYME PHOSPHORYLATION; ERYTHEMA; EYE TOXICITY; FAINTNESS; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; GENE; GENE MUTATION; GNAQ GENE; GYNECOLOGIC CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; LIVER CANCER; LUNG CANCER; LYMPHEDEMA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NAUSEA; NEUROTOXICITY; NON MELANOMA SKIN CANCER; OPEN STUDY; PANCREAS CANCER; PAPULAR RASH; PERIVASCULAR EPITHELIOID CELL TUMOR; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PUSTULE; QT PROLONGATION; RECOMMENDED DRUG DOSE; RETINA VEIN OCCLUSION; SARCOMA; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; SOMNOLENCE; STOMACH CANCER; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DIPHENYLAMINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; SULFONAMIDES; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84874888117     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3529     Document Type: Article

References (33)

1. Hilger RA, Scheulen ME, Strumberg D. The RAS-RAF-MEK-ERK pathway in the treatment of cancer. Onkologie 2002;25: 511-8.
2. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26: 3291-310.
3. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008;14: 342-6.
4. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49: 4682-9.
5. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-KDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18: 813-22.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
7. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, et al. BRAF and RAS mutations in human cancer and melanoma. Cancer Res 2002;62: 6997-7000.
8. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63: 1454-7.
9. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12: 1623-9.
10. Wong C-M, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008;28: 160-74.
11. Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol 2010;3: 8.
12. Collisson EA, De A, Suzuki H, Gambhir SS, Kolodney MS. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf- MAPK cascade. Cancer Res 2003;63: 5669-73.
13. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-62.
14. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004; 11: 1192-7.
15. Thompson N, Lyons J. Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005;5: 350-6.
16. Iverson C, Larson G, Lai C, Yeh LT, Dadson C, Weingarten P, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;69: 6839-47.
17. Chang Q, Chapman MS, Miner JN, Hedley DW. Antitumor activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts. BMC Cancer 2010;10: 515.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
19. Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26: 2139-46.
20. LoRusso PM, Krishnamurthi SS, Rinehart JJ, Nabell LM, Malburg L, Chapman PB, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16: 1924-37.
21. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, Demarini DJ, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13: 782-9.
22. Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 2012;18: 4794-805.
23. Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011;29: 1114-21.
24. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010;16: 1613-23.
25. LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI- 1040 in patients with advanced malignancies. J Clin Oncol 2005;23: 5281-93.
26. Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22: 4456-62.
27. Rosen LS, Galatin P, Fehling JM, Laux I, Dinolfo M, Frye J, et al.Aphase 1 dose-escalation study of XL518, a potentMEKinhibitor administered orally daily to subjects with solid tumors. J Clin Oncol 26: 2008 (May 20 suppl; abstr 14585).
28. Haura EB, Ricart AD, Larson TG, Stella PJ, Bazhenova L, Miller VA, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16: 2450-7.
29. Hainsworth JD, Cebotaru CL, Kanarev V, Ciuleanu TE, Damyanov D, Stella P, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010;5: 1630-6.
30. Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, et al. Multiinstitutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 2011;29: 2357-63.
31. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 2012;18: 4345-55.
32. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 2010;467: 596-9.
33. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 2012;11: 1143-54.